All In Biotech

Drug Trial Radar · NCT05601882

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects With Moderate to Severe Atopic Dermatitis (Level-Up)

Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 920 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

920

Actual

Start

Nov 28, 2022

Primary completion

Mar 19, 2024

Study completion Aug 8, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed. Upadacitinib and dupilumab are approved drugs for the treatment of moderate to severe atopic dermatitis (AD). The study is comprised of a 35-day Screening Period, a 16-week treatment Period 1 and a 16-week treatment Period 2. Participants are randomly assigned to 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab in Period 1. There is a 30-day or 12-week follow-up visit for those on upadacitinib or dupilumab respectively, who will not enter Period 2. In Period 2, participants will receive upadacitinib Dose A or Dose B for 16 weeks, followed by a 30-day follow-up visit. Approximately 880 adolescent and adult participants ages 12 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 330 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Atopic Dermatitis

Interventions

  • DupilumabDrug

    Dupilumab is administered as a subcutaneous (SC) injection.

  • UpadacitinibDrug

    Extended-release tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16Time frame: Baseline and Week 16

Locations

257 sites in 29 countries. Site status is shown where the registry gives one.

  • Medical Dermatology Specialists /ID# 250212

    Phoenix, Arizona

  • Alliance Dermatology and Mohs Center /ID# 249671

    Phoenix, Arizona

  • Clinical Trials Institute - Northwest Arkansas /ID# 249838

    Fayetteville, Arkansas

  • Arkansas Research Trials /ID# 250722

    North Little Rock, Arkansas

  • Joseph Raoof Md,Inc /Id# 250211

    Encino, California

  • First OC Dermatology /ID# 250686

    Fountain Valley, California

  • Antelope Valley Clinical Trials /ID# 249946

    Lancaster, California

  • Dermatology Research Associates /ID# 249829

    Los Angeles, California

  • University of California Davis Health /ID# 250044

    Sacramento, California

  • Clinical Trials Research Institute /ID# 250213

    Thousand Oaks, California

  • Western States Clinical Res /ID# 250274

    Wheat Ridge, Colorado

  • UConn Health /ID# 253807

    Farmington, Connecticut

  • Yale Center for Clinical Investigation /ID# 254791

    New Haven, Connecticut

  • Clearlyderm Dermatology /ID# 250457

    Boca Raton, Florida

  • Skin Care Research Boca Raton /ID# 250458

    Boca Raton, Florida

  • Olympian Clinical Research /ID# 250453

    Clearwater, Florida

  • Skin Care Research - Hollywood /ID# 250459

    Hollywood, Florida

  • Solutions Through Adv Rch /ID# 250455

    Jacksonville, Florida

  • GSI Clinical Research, LLC /ID# 250768

    Margate, Florida

  • D&H National Research Centers /ID# 250734

    Miami, Florida

  • Florida International Rsrch cr /ID# 249667

    Miami, Florida

  • Wellness Clinical Research - Miami Lakes /ID# 250236

    Miami Lakes, Florida

  • Tory P Sullivan, MD PA /ID# 251136

    North Miami Beach, Florida

  • Precision Clinical Research /ID# 250990

    Sunrise, Florida

  • Advanced Clinical Research Institute /ID# 250460

    Tampa, Florida

  • Metabolic Research Inst /ID# 250046

    West Palm Beach, Florida

  • Treasure Valley Medical Research /ID# 250727

    Boise, Idaho

  • Dawes Fretzin, LLC /ID# 250276

    Indianapolis, Indiana

  • Randall Dermatology of West Lafayette /ID# 250234

    West Lafayette, Indiana

  • Beth Israel Deaconess Medical Center /ID# 251212

    Boston, Massachusetts

  • Beacon Clinical Research, LLC /ID# 251412

    Quincy, Massachusetts

  • Clarkston Dermatology /ID# 250225

    Clarkston, Michigan

  • Henry Ford Medical Center - New Center One /ID# 250228

    Detroit, Michigan

  • Cleaver Dermatology /ID# 250725

    Kirksville, Missouri

  • MediSearch Clinical Trials /ID# 250272

    Saint Joseph, Missouri

  • Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 250616

    Lincoln, Nebraska

  • Physician Research Collaboration, LLC /ID# 251099

    Lincoln, Nebraska

  • Montefiore Medical Center - Moses Campus /ID# 251214

    The Bronx, New York

  • Derm of Greater Columbus /ID# 250049

    Bexley, Ohio

  • Univ Hosp Cleveland /ID# 250699

    Cleveland, Ohio

Showing 40 of 257 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.